Puma BiotechnologyPBYI
PBYI
About: Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Employees: 172
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
756% more call options, than puts
Call options by funds: $137K | Put options by funds: $16K
147% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 19
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
17% more capital invested
Capital invested by funds: $75.9M [Q3] → $89.1M (+$13.2M) [Q4]
10% more funds holding
Funds holding: 100 [Q3] → 110 (+10) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
4.17% less ownership
Funds ownership: 60.63% [Q3] → 56.47% (-4.17%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$7
145%
upside
Avg. target
$7
145%
upside
High target
$7
145%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Edward White 24% 1-year accuracy 36 / 149 met price target | 145%upside $7 | Buy Reiterated | 28 Feb 2025 |
Financial journalist opinion
Based on 4 articles about PBYI published over the past 30 days
Neutral
Business Wire
2 weeks ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that inducement awards were granted to staff hired in March, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Seeking Alpha
2 weeks ago
Puma SE: Undervalued With Tailwinds Ahead
Puma SE is poised for a turnaround with strong growth plans in the US market and strategic athlete endorsements, leading me to assign a "Buy" recommendation. Despite recent subpar financial performance, Puma's robust dividend growth history and stable payout ratio indicate a solid foundation for future shareholder returns. My DCF analysis reveals that Puma is undervalued, with an intrinsic value per share of $5.35, representing a 78.3% upside from current levels.
Neutral
Business Wire
3 weeks ago
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR Annual Meeting.
Positive
Seeking Alpha
4 weeks ago
PUMA SE: This Is The Right Time To Buy
Puma SE's stock has dropped nearly 50% year-to-date, with an additional 20% decline following its Q4 earnings, creating a potential value opportunity for long-term investors. Despite consistent revenue growth, Puma has struggled with profitability as rising operating expenses have outpaced sales, leading to stagnant net income over the past several years. High-profile collaborations with cultural icons like Rihanna, A$AP Rocky, and top sports teams such as Scuderia Ferrari's F1 team are driving increased brand engagement and market relevance.
Neutral
Business Wire
1 month ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards t.
Neutral
Business Wire
1 month ago
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on Tuesday, March 11, at Barclays 27th Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach. A live webcast of the presentation will be available on the Puma Biotechnology website at https://www.pumabiotechnology.com. The.
Positive
Zacks Investment Research
1 month ago
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
Zacks Investment Research
1 month ago
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates
Puma Biotechnology beats on fourth-quarter 2024 earnings and sales. The company issues a fresh financial guidance for 2025.
Neutral
Seeking Alpha
1 month ago
Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call Transcript
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – President and Chief Executive Officer Jeff Ludwig – Chief Commercial Officer Maximo Nougues – Chief Financial Officer Conference Call Participants Ed White – H.C. Wainwright Marc Frahm – TD Cowen Operator Good afternoon.
Positive
Zacks Investment Research
1 month ago
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates
Puma Biotech (PBYI) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.31 per share a year ago.
Charts implemented using Lightweight Charts™